Somaxon Pharmaceuticals To Present At The Stifel Nicolaus 2012 Healthcare Conference

SAN DIEGO, Aug. 27, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that Richard W. Pascoe, Somaxon's president and chief executive officer, will present at Stifel Nicolaus 2012 Healthcare Conference at the Four Seasons Hotel in Boston on Thursday, September 6, at 10:20 a.m. Eastern Time.

A live webcast of the presentation will be available in the Investor Relations section of the company's Web site at http://investors.somaxon.com/events.cfm. The webcast will be accessible following conclusion of the live event and archived for approximately 30 days following the conference.

About Somaxon Pharmaceuticals, Inc.

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon's product Silenor, available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.

For more information, please visit the company's web site at www.somaxon.com .

The Somaxon Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13679
CONTACT: Tran Nguyen / CFO         Somaxon Pharmaceuticals, Inc.         (858) 876-6500                  Matt Sheldon/ Investor Relations         PondelWilkinson Inc.         (310) 279-5975

Somaxon Pharmaceuticals, Inc. Logo

If you liked this article you might like

Somaxon Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Somaxon Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Transcept Wins Sleeping Pill Approval

Transcept Wins Sleeping Pill Approval

Biotech Stock Mailbag: Somaxon, Transcept

Biotech Stock Mailbag: Somaxon, Transcept

Biotech Stock Mailbag: Generex Bio

Biotech Stock Mailbag: Generex Bio

Biotech Stock Mailbag: Avanir Pharma

Biotech Stock Mailbag: Avanir Pharma